Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today the appointment of Christina Herder, as Executive Vice President, Strategic Business...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that data from the initial phase IIa study of MIV-711 in patients...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication. The Leukotide project...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that it has appointed Erik Björk as Chief Financial Officer effective...
Read moreJuly - September Significant events during the quarter Positive topline results from phase IIa osteoarthritis study showed disease-modifying benefit and an...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Read moreStockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today communicates phase IIb data on JNJ-4178, the triple combination consisting of simeprevir,...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that data from the initial phase IIa study of MIV-711 in patients...
Read moreStockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that phase II efficacy and safety data in patients with Mycosis...
Read moreStockholm, Sweden and Alderley Park, England - Medivir AB (Nasdaq Stockholm: MVIR) and AMR Centre Ltd (AMRC) today announce signing of...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top line data from MIV-711-201, the 6-month initial phase IIa...
Read more